Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction...

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Exenatide has demonstrated cardioprotective effects in ST-segment elevation myocardial infarction (STEMI).
• The impact of liraglutide, a glucagon-like peptide-1 analogue, on STEMI patients requires further investigation.
• Primary percutaneous coronary intervention is a standard treatment for STEMI.

Purpose of the Study:

• To evaluate the efficacy of liraglutide in improving left ventricular function in STEMI patients undergoing primary percutaneous coronary intervention.
• To assess the impact of liraglutide on cardiac function and related biomarkers post-STEMI.
• To determine if liraglutide offers benefits beyond standard reperfusion therapy.

Main Methods:

• A randomized controlled trial involving 92 STEMI patients, with 85 completing the study.
• Patients received either liraglutide or placebo for 7 days, initiated before intervention.
• Left ventricular function was assessed using transthoracic echocardiography at 3 months.

Main Results:

• Liraglutide significantly improved left ventricular ejection fraction by +4.1% at 3 months (P < .001).
• A trend towards reduced no-reflow was observed in the liraglutide group (7% vs. 15%, P = .20).
• Liraglutide demonstrated significant improvements in stress hyperglycemia and favorable changes in inflammation and endothelial function markers.

Conclusions:

• A short 7-day course of liraglutide is associated with a mild improvement in left ventricular ejection fraction at 3 months in STEMI patients.
• Liraglutide may offer additional benefits in managing hyperglycemia and improving vascular function post-STEMI.
• Further research is warranted to explore the long-term cardiovascular benefits of liraglutide in STEMI patients.